Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.
- Revenue
- −0.28%
- EPS
- −154.6%
- Free cash flow
- +38.8%
- Total debt
- −89.4%
Quarter to September 2026, against a year earlier
Follow VTRS
Alert me
Viatris Inc. (VTRS) P/B ratio
As of 5 November 2026, Viatris Inc. (VTRS) trades at a P/B ratio of 1.6×. Over the past ten years it has ranged from 0.4× (March 2021) to 7.4× (March 2015); the current reading is higher than 75% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 1.8× and below the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 1.0× | 24.27% |
| FY2024 | 0.8× | 19.34% |
| FY2023 | 0.7× | 2.05% |
| FY2022 | 0.7× | (17.98%) |
| FY2021 | 0.8× | 62.61% |
| FY2020 | 0.5× | (43.73%) |
| FY2019 | 0.9× | (24.72%) |
| FY2018 | 1.2× | (33.09%) |
| FY2017 | 1.7× | (4.06%) |
| FY2016 | 1.8× | (30.97%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 1.5× | 16.27% |
| Jun 2026 | 1.3× | 21.65% |
| Mar 2026 | 1.1× | 7.49% |
| Dec 2025 | 1.0× | 30.77% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| VTRS Viatris Inc. | 1.6× |
| ELAN Elanco Animal Health Incorporated compare | 1.8× |
| HLN Haleon PLC Sponsored ADR compare | 1.9× |
| RDY Dr. Reddy's Laboratories Ltd compare | 3.0× |
| UTHR United Therapeutics Corporation compare | 3.8× |
| ALKS Alkermes plc compare | 4.0× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.2× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 6.1× |
| ZTS Zoetis Inc. compare | 10.8× |
| Drug Manufacturers Specialty & Generic industry median | 1.8× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement